Cleveland Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>CB</div>
CBLI -- USA Stock  

USD 4.06  0.03  0.74%

The stock goes through an active upward rally. Cleveland BioLabs Enterprise Value is most likely to decrease significantly in the upcoming years. The preceding year's Enterprise Value was reported at 5.31 Million. The current Market Capitalization is estimated to increase to about 7 M, while Net Income Per Employee is projected to decrease to (103 K). While some of us are becoming more enthusiastic about healthcare space, let's concentrate on Cleveland BioLabs in greater detail to make a better estimate of its debt utilization.
Published over three weeks ago
View all stories for Cleveland BioLabs | View All Stories
How much will Cleveland BioLabs owe in January?
The current Long Term Debt to Equity is estimated to decrease to 0.0138. The current Debt to Equity Ratio is estimated to decrease to -0.28This firm has a current ratio of 6.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Cleveland BioLabs holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -1.3145, which signifies a somewhat significant risk relative to the market. Let's try to break down what Cleveland's beta means in this case. As returns on the market increase, returns on owning Cleveland BioLabs are expected to decrease by larger amounts. On the other hand, during market turmoil, Cleveland BioLabs is expected to outperform it. Although it is vital to follow Cleveland BioLabs historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. Our philosophy in foreseeing future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Cleveland BioLabs expected return of 1.19 will be sustainable into the future, we have found twenty-eight different technical indicators, which can help you to check if the expected returns are sustainable. Use Cleveland BioLabs potential upside, rate of daily change, and the relationship between the sortino ratio and skewness to analyze future returns on Cleveland BioLabs.
Cleveland BioLabs financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Cleveland BioLabs, including all of Cleveland BioLabs's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Cleveland BioLabs assets, the company is considered highly leveraged. Understanding the composition and structure of overall Cleveland BioLabs debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

Understanding Cleveland Total Debt

Cleveland BioLabs liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Cleveland BioLabs has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Cleveland BioLabs balance sheet include debt obligations and money owed to different Cleveland BioLabs vendors, workers, and loan providers. Below is the chart of Cleveland main long-term debt accounts currently reported on its balance sheet.
You can use Cleveland BioLabs financial leverage analysis tool to get a better grip on understanding its financial position

How important is Cleveland BioLabs's Liquidity

Cleveland BioLabs financial leverage refers to using borrowed capital as a funding source to finance Cleveland BioLabs ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Cleveland BioLabs financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Cleveland BioLabs's total debt and its cash.

Sale by Yakov Kogan of 300 shares of Cleveland BioLabs

Legal trades by Cleveland BioLabs insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Cleveland BioLabs insider trading alert for sale of common stock by Yakov Kogan, COO Secretary, on 28th of April 2020. This event was filed by Cleveland Biolabs Inc with SEC on 2010-02-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Cleveland BioLabs Investor Appetite?

The company reported the previous year's revenue of 631.84 K. Net Loss for the year was (2.41 M) with loss before overhead, payroll, taxes, and interest of (543.01 K).

Liabilities Breakdown

Total Liabilities1.08 Million
Current Liabilities1.08 Million
Long-Term Liabilities7,813.45

Our perspective of the current Cleveland BioLabs rise

The downside deviation is down to 5.19 as of today. As of the 25th of December, Cleveland BioLabs shows the risk adjusted performance of 0.144, and Mean Deviation of 4.36. Cleveland BioLabs technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Cleveland BioLabs, which can be compared to its rivals. Please confirm Cleveland BioLabs jensen alpha, and the relationship between the coefficient of variation and potential upside to decide if Cleveland BioLabs is priced correctly, providing market reflects its regular price of 3.72 per share. Given that Cleveland BioLabs has jensen alpha of 1.15, we suggest you to validate Cleveland BioLabs's prevailing market performance to make sure the company can sustain itself at a future point.

Our Conclusion on Cleveland BioLabs

While some other entities under the biotechnology industry are still a bit expensive, Cleveland BioLabs may offer a potential longer-term growth to stockholders. With a less-than optimistic outlook for your 30 days horizon, it may be a good time to exit some or all of your Cleveland BioLabs holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Cleveland BioLabs.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Cleveland BioLabs. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com